Latest Payments News

IMDEX Limited has announced a fully franked ordinary dividend of AUD 0.015 per share, signaling steady shareholder returns for the half-year ending December 2024.

ASB reported a modest 1% increase in cash net profit after tax for the half-year ending December 2024, underpinned by rising lending volumes and strategic investments in housing and fraud prevention amid New Zealand's gradual economic recovery.

Suncorp Group Limited has announced a cash return of capital of AUD 3.00 per share, backed by shareholder and regulatory approvals, with payments scheduled for early March 2025.

Suncorp Group Limited has outlined a detailed timetable for its capital return, share consolidation, and dividend payments, marking a significant phase in its capital management strategy.

Suncorp Group Limited delivered a robust half-year performance with a $1.1 billion net profit, driven by favourable natural hazard conditions and the strategic sale of Suncorp Bank. The insurer plans a substantial $4.1 billion return to shareholders, underscoring its strong capital position and growth ambitions.

Amotiv Limited has announced a fully franked interim dividend of AUD 0.185 per share for the half-year ending December 2024, signaling steady financial health and shareholder returns.

Suncorp Group Limited has announced a combined ordinary and special dividend totaling AUD 0.63 per security, fully franked and backed by APRA approval for a capital reduction. The payment is scheduled for mid-March 2025.

The Commonwealth Bank of Australia has released its December 2024 Basel III Pillar 3 report, reaffirming strong capital adequacy and liquidity positions despite evolving regulatory frameworks.

Commonwealth Bank of Australia delivered a solid half-year performance with a 6% increase in net profit after tax and declared a fully franked interim dividend of $2.25 per share, underscoring resilience amid economic challenges.

Commonwealth Bank of Australia announces a fully franked ordinary dividend of AUD 2.25 per share, payable March 28, 2025, reflecting solid financial results for the period ending December 31, 2024.

Argenica Therapeutics reported a 16% reduction in half-year losses to $1.19 million, buoyed by a 29% increase in other income largely from R&D tax incentives, as it advances its neuroprotective drug development.

Sarama Resources has completed the second tranche of its A$2 million equity placement, issuing options to institutional investors after shareholder approval. The funds are earmarked for advancing exploration and supporting working capital.